Extract
Sarcoidosis most commonly affects the thoracic lymph nodes, lung parenchyma and airway in nearly two-thirds of patients [1]. We previously reported that airflow limitation in Japanese outpatients was associated with radiographic stage IV disease, older age, smoking and bronchovascular bundle thickening on high-resolution computed tomography (HRCT) [2]. Airway hyperresponsiveness (AHR) can be another potential predisposing factor of airflow limitation [1, 3]. Impulse oscillometry (IOS) is an effort-independent and noninvasive method of assessing respiratory physiology and may detect more subtle changes than spirometry [4]. Thus, a multidisciplinary approach including AHR provocation test and IOS may provide novel insights into airway involvement of sarcoidosis compared to classical spirometric assessments. We conducted a prospective observational study to comprehensively evaluate airway involvement in patients with pulmonary sarcoidosis and investigate the impacts of various aspects of airway involvement on the long-term outcome. This study was approved by the Ethics Committee of Kyoto University (Kyoto, University; institutional board number E-530), with all subjects granting written informed consent.
Abstract
IOS can predict airway hyperresponsiveness and long-term outcome in patients with pulmonary sarcoidosis http://ow.ly/bkQH307VD4m
Acknowledgements
We appreciate M. Jinnai, K. Otsuka, T. Takeda, H. Nakaji, T. Tajiri, H. Inoue, T. Iwata, T. Nagasaki and Y. Kanemitsu (Dept of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan) for the measurement of FeNO and T. Izumi (Kyoto Central Clinic, Clinical Research Center, Kyoto, Japan) for academic advice. We also thank T. Toki, N. Kimura and S. Tamura (Dept of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan) for help with manuscript preparation.
Footnotes
Support statement: This study was supported in part by a grant from Japan's Ministry of Health, Labor and Welfare to the Diffuse Lung Diseases Research Group, the Respiratory Failure Study Group, and the Research Program of Intractable Disease. Other support included the Japan Society for the Promotion of Science KAKENHI (grant numbers JP25860642, JP26461187 and JP16K09534) and a grant from the Japan Intractable Diseases Research Foundation and the Practical Research Project for Rare Intractable Diseases from Japan Agency for Medical Research and development, AMED (No. 15ek0109079h0001). The Dept of Respiratory Care and Sleep Control Medicine (Kyoto University, Kyoto, Japan) is funded by endowments from Philips Respironics, Teijin Pharma Ltd, Fukuda Denshi Inc. and Fukuda Lifetec Keiji. Funding information for this article has been deposited with the Open Funder Registry.
Conflict of interest: Disclosures can be found alongside this article at erjor.ersjournals.com
- Received September 28, 2016.
- Accepted December 10, 2016.
- Copyright ©ERS 2017
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.